These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38196077)

  • 1. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
    Cohen AT; Creeper KJ; Alikhan R; Er C; Connors JM; Huisman MV; Munoz A; Vescovo G; Bauersachs R; Ageno W; Agnelli G; Becattini C
    Thromb Haemost; 2024 Jul; 124(7):676-683. PubMed ID: 38196077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
    Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
    Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
    Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
    Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
    Ageno W; Vedovati MC; Cohen A; Huisman M; Bauersachs R; Gussoni G; Becattini C; Agnelli G
    Thromb Haemost; 2021 May; 121(5):616-624. PubMed ID: 33202447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism.
    Cohen AT; Dhamane AD; Liu X; Singh R; Han S; Stellhorn R; Wang J; Luo X
    J Natl Compr Canc Netw; 2024 Aug; 22(6):397-403. PubMed ID: 39151451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
    N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
    McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
    J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
    Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
    Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
    Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
    Giustozzi M; Connors JM; Ruperez Blanco AB; Szmit S; Falvo N; Cohen AT; Huisman M; Bauersachs R; Dentali F; Becattini C; Agnelli G
    J Thromb Haemost; 2021 Nov; 19(11):2751-2759. PubMed ID: 34260816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.
    McBane RD; Loprinzi CL; Zemla T; Tafur A; Sanfilippo K; Liu JJ; Garcia DA; Heun J; Gundabolu K; Onitilo AA; Perepu U; Drescher MR; Henkin S; Houghton D; Ashrani A; Billett H; McCue SA; Lee MK; Le-Rademacher JG; Wysokinski WE;
    J Thromb Haemost; 2024 Jun; 22(6):1704-1714. PubMed ID: 38537780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
    Agnelli G; Becattini C; Bauersachs R; Brenner B; Campanini M; Cohen A; Connors JM; Fontanella A; Gussoni G; Huisman MV; Lambert C; Meyer G; Muñoz A; Abreu de Sousa J; Torbicki A; Verso M; Vescovo G;
    Thromb Haemost; 2018 Sep; 118(9):1668-1678. PubMed ID: 30103252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
    Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
    J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
    Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
    [No Abstract]   [Full Text] [Related]  

  • 18. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
    Agnelli G; Muñoz A; Franco L; Mahé I; Brenner B; Connors JM; Gussoni G; Hamulyak EN; Lambert C; Suero MR; Bauersachs R; Torbicki A; Becattini C
    Thromb Haemost; 2022 May; 122(5):796-807. PubMed ID: 34530482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.